You are here

Global

Merck will join with rival Johnson & Johnson to step up J&J's Covid vaccine production

 

Under a White House-brokered deal, Merck will help boost supplies of its rival Johnson & Johnson’s vaccine

The pharmaceutical giant Merck & Co will help manufacture the new Johnson & Johnson coronavirus vaccine under an unusual deal, brokered by the White House, that could substantially increase the supply of the new vaccine and ramp up the pace of vaccination just as worrisome new variants of the virus have been found in the United States.

The arrangement, first reported by The Washington Post on Tuesday, comes just days after the Food and Drug Administration granted emergency authorization to the Johnson & Johnson vaccine.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

New Varient in Brazil causes concern, infected previous COVID-19 victims

In just a matter of weeks, two variants of the coronavirus have become so familiar that you can hear their inscrutable alphanumeric names regularly uttered on television news.

B.1.1.7, first identified in Britain, has demonstrated the power to spread far and fast. In South Africa, a mutant called B.1.351 can dodge human antibodies, blunting the effectiveness of some vaccines.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Twitter taking more action aganst COVID vaccine misinformation

SAN FRANCISCO (AP) — Twitter says it has begun labeling tweets that include misleading information about COVID-19 vaccines and using a “strike system” to eventually remove accounts that repeatedly violate its rules.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

New Study Shows One Dose of AstraZeneca Vaccine Protects Older People

A single shot of either the Oxford-AstraZeneca or the Pfizer-BioNTech Covid jab reduces the chance of needing hospital treatment by more than 80%, an analysis in England shows.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Russians say its Sputnik V vaccines performs well against COVID mutations

MOSCOW (Reuters) - A Russian trial testing the effectiveness of revaccination with the Sputnik V shot to protect against new mutations of the coronavirus is producing strong results, researchers said on Saturday.

Last month President Vladimir Putin ordered a review by March 15 of Russian-produced vaccines for their effectiveness against new variants spreading in different parts of the world.

“(A) recent study carried out by the Gamaleya Centre in Russia showed that revaccination with Sputnik V vaccine is working very well against new coronavirus mutations, including the UK and South African strains of coronavirus,” said Denis Logunov, a deputy director of the centre, which developed the Sputnik V shot.

Results of the trial are expected to be published soon, but this was the first indication of how the tests are going. No further details were available yet.

So-called viral vector shots - such as Sputnik V and a shot developed by AstraZeneca - use harmless modified viruses as vehicles, or vectors, to carry genetic information that helps the body build immunity against future infections. ...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Global
howdy folks